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Abstract
Background: Neuregulin 1 (NRG1) is a key candidate susceptibility gene for both schizophrenia (SCZ) and bipolar disorder
(BPD). The function of the NRG1 transmembrane proteins is regulated by cleavage. Alteration of membrane bound-NRG1
cleavage has been previously shown to be associated with behavioral impairments in mouse models lacking expression of
NRG1-cleavage enzymes such as BACE1 and gamma secretase. We sought to determine whether alterations in NRG1
cleavage and associated enzymes occur in patients with SCZ and BPD.
Methodology/Principal Findings: Using human postmortem brain, we evaluated protein expression of NRG1 cleavage
products and enzymes that cleave at the external (BACE1, ADAM17, ADAM19) and internal (PS1-gamma secretase) sides of
the cell membrane. We used three different cohorts (Controls, SCZ and BPD) and two distinct brain regions: BA9-prefrontal
cortex (Controls (n=6), SCZ (n=6) and BPD (n=6)) and hippocampus (Controls (n=5), SCZ (n=6) and BPD (n=6)). In BA9,
the ratio of the NRG1 N-terminal fragment relative to full length was significantly upregulated in the SCZ cohort (Bonferroni
test, p=0.011). ADAM17 was negatively correlated with full length NRG1 levels in the SCZ cohort (r=–0.926, p=0.008). In
the hippocampus we found significantly lower levels of a soluble 50 kDa NRG1 fragment in the two affected groups
compared the control cohort (Bonferroni test, p=0.0018). We also examined the relationship of specific symptomatology
criteria with measures of NRG1 cleavage using the Bipolar Inventory of Signs and Symptoms Scale (BISS) and the
Montgomery A ˚sberg Depression Rating Scale (MADRS). Our results showed a positive correlation between ADAM19 and
psychosis (r=0.595 p=0.019); PS1 and mania (r=0.535, p=0.040); PS1 and depression (r=0.567, p=0.027) in BA9, and
BACE1 with anxiety (r=0.608, p=0.03) in the hippocampus.
Conclusion/Significance: Our preliminary findings suggest region-specific alterations in NRG1 cleavage in SCZ and BPD
patients. These changes may be associated with specific symptoms in these psychiatric disorders.
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Introduction
Schizophrenia (SCZ) and bipolar disorder (BPD), two of the
most severe psychiatric disorders, are complex disorders with both
genetic and environmental underpinnings. Numerous genes have
been reported to be associated with these disorders, and thought to
possibly contribute to increased risk for their development. Of
these, Neuregulin 1 (NRG1) has been shown to be linked with both
SCZ [1–2] and BPD [3] in different populations worldwide. Over
20 different isoforms of the NRG1 gene are generated via
alternative splicing. These proteins regulate many important
functions in the nervous system including myelination, glial cell
migration and synapse formation. NRG1 Type III is the most
abundant isoform in the brain [4]. It is synthesized as a membrane
bound pro-form that is cleaved by enzymes to generate the
bioactive extracellular and intracellular fragments of the protein.
The extracellular fragment contains an EGF domain which
interacts with ErbB tyrosine kinase receptors and activates the
MAPK, PKC and AKT pathways [5]. Enzymes responsible for
external cleavage include beta-site amyloid precursor protein
cleaving enzyme 1 (BACE1), and a disintegrin and a-metallopro-
teinases (ADAM17, 19) [6–7]. These enzymes generate the N
terminal fragment (NTF) on the external, and the C-terminal
fragment (CTF) on the internal side of the membrane. Further
cleavage of the intracellular CTF by gamma secretase generates
the intracellular domain (ICD), which is thought to regulate gene
expression [8]. Interestingly, BACE1 and Aph1BC (a component
of the gamma secretase complex) knock-out mouse models, in
which NRG1 cleavage is impaired, exhibit alterations in behaviors
such as deficits in prepulse inhibition, cognitive impairments,
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36431
Southwest
Psychiatry,  University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of Americaalterations in social recognition and interaction [9–10], suggesting
that imbalances in NRG1 cleavage may cause behavioral
abnormalities similar to those observed in SCZ. In this study we
sought to test the hypothesis that deficits in NRG1 cleavage and
NRG1- cleavage enzymes may occur in SCZ in the hippocampus
[11–14] and dorsal lateral prefrontal cortex [15–16]. Our
laboratory previously identified a novel missense polymorphism
(V.L) in the transmembrane region of NRG1 that is associated
with schizophrenia [17]. This amino acid change has more
recently been shown to impede gamma-secretase cleavage of the
NRG1 CTF [9]. We therefore hypothesized that reduced levels of
the NRG1 ICD would be found in the postmortem brain of SCZ
patients. In addition, given the studies showing behavioral
alterations in BACE-1 knock-out mice, we hypothesized that
alterations in NRG1 external cleavage would be found in SCZ.
Previous postmortem studies investigating NRG1 protein expres-
sion have shown different results, ranging from no changes
[18,19], a decrease in a 50 kDa band in BA6 in SCZ [20], and an
increase in a 53 kDa band in the prefrontal cortex cytoplasmic
fraction of SCZ patients [21]. Our study is novel in that we
assessed levels of different NRG1 cleavage products in two distinct
cellular fractions- membrane and soluble. Our reasons for doing so
were two fold. First, given that NRG1 Type III has two
transmembrane regions, and its cleavage products are tethered
to the membrane, we anticipated that the use of the membrane
fraction would facilitate detection of these products. Similarly,
cleavage on the internal side would generate fragments detectable
in the soluble fraction. Second, the field of NRG1 research is
plagued with a dearth of non-specific antibodies, and probing each
fraction individually eliminated some of the non specificity. In
addition to NRG1 levels, we investigated levels of the main
enzymes that are involved in cleavage of NRG1, to test the
hypothesis that alterations in enzyme levels would correlate with
changes seen in NRG1 cleavage. We used three groups (control,
SCZ and BPD patients) and two different brain regions (prefrontal
cortex and hippocampus). Based on the diverse functionality of
these two regions, we hypothesized that we would observe region
specific changes in NRG1 cleavage. Additionally, because of the
interest in determining intermediate phenotypes (endophenotypes)
and assessing symptomatology that cuts across diagnostic criteria,
we examined whether specific symptom clusters were associated
with the biological measures being tested. To do so, we analyzed
symptoms experienced in the last week of life using scales of
symptom severity such as the MINI [22] Bipolar Inventory of
Signs and Symptoms Scale (BISS) [23] and the Montgomery
A ˚sberg Depression Rating Scale (MADRS) [24]. These studies will
shed light as to the role of NRG1 in development of SCZ and
BPD.
Results
Sample Demographics and Variables
For the BA9 comparisons, no significant differences were found
between the demographic variables pH, PMI, brain weight, race
and age (Tables S1 and S2). Given that the control group consisted
solely of males, to determine if gender had an effect on protein
levels, we combined the SCZ and BPD groups and found no
significant differences on the effect of gender (T test, p=0.07) on
protein levels. For the hippocampal area studies, age was
significantly different between the 3 groups, (F (2, 14) =6.040,
p=0.013) (Bonferroni post hoc test showed the BPD cohort to be
significantly different from controls, p=0.011). Pearson’s correla-
tion analyses were carried out between the different demographic
criteria (age, race, sex, pH, PMI, brain weight) and all the different
proteins assayed. In BA9, pH was found to correlate with
ADAM17 (r=–0.523, p=0.026); NRG1 NTF (r=0.530,
p=0.024) and NRG1 FL (r=0.487, p=0.04); brain weight was
shown to correlate with NRG1 FL (r=0.473, p=0.047). In the
hippocampus, sex correlated with BACE1 levels (r=0.563,
p=0.018) and race correlated with NTF (r=–0.541, p=0.025);
brain weight was shown to negatively correlate with BACE1 levels
(r=–0.527, p=0.030). Based on these results, ANCOVA was used
to determine differences between groups using pH as a covariate
for ADAM17, NRG1 NTF and FL; brain weight as a covariate for
NRG1 FL in BA9; sex as a covariate for BACE 1, and race as
a covariate for NTF in the hippocampus. ADAM17 was found to
be significantly different between groups when using pH as
a covariate (F (2, 15)=7.166, p=0.007). None of the other
ANCOVAs were significant. Thereafter ANOVA was used to
determine differences between groups for the remaining proteins
(that did not show significant Pearson’s correlations with any of the
demographic variables), followed by post hoc analyses using
Bonferroni test.
Four different classes of medication were used by the disease
cohort, namely-antipsychotics, antidepressants, benzodiazepines
and mood stabilizers (Table S3). Since the cohort sizes were too
small to determine the effects of each of the different classes of
drugs, we stratified the disease cohort into two groups, those that
were on medication and those that were not on any medication.
No effects of medication on protein levels were observed in the
combined SCZ and BPD group in BA9 (T test, p=0.376) or
hippocampus (T test, p=0.155).
NRG1 Protein Expression in Different Brain Regions in
SCZ and BPD
For detection of the NRG1 full length and post-external
cleavage fragments, we used an antibody against NRG1 type III
(antibody ab5551), that recognizes the Full length (FL) (expected
size-130 kDa) and the N-terminal fragment (NTF) (expected size -
76 kDa) [25]. Given that NRG1 type III has two transmembrane
domains, the NTF remains attached to the membrane after initial
cleavage by external cleavage enzymes [25]. For detection of the
soluble internal cleavage product, we used an antibody against the
cytoplasmic tail (sc348 antibody), which is cleaved by gamma
secretase to generate the intracellular domain (ICD) in the soluble
fraction. The expected size of this band is 53 kDa [20].
In BA9, the FL 130 kDa and NTF 70 kDa protein bands were
detected in the membrane fraction. ANOVA showed no
significant differences in the levels of these bands between the
three different patient groups (Fig.1A). Based on the studies
showing BACE1 and gamma secretase knockout mice with SCZ-
like behavioral abnormalities, we had an apriori hypothesis that the
cleavage impairments would be specific to SCZ. Therefore, T tests
were performed and significantly higher levels of the NTF in SCZ
compared to controls (p=0.0335) (Fig.1B), but not in BPD
compared to controls, were found. Furthermore, the ratio of the
NTF to FL was significantly higher in the SCZ cohort by ANOVA
(F (2, 15)=6.997, p=0.007) (Fig.1C). Bonferroni post hoc test
showed the SCZ group to be significantly different from controls
(p=0.011) and BPD (p=0.027), providing additional evidence of
altered NRG1 extracellular processing in SCZ (Fig.1). In the
soluble fraction, no significant differences between groups were
found in the levels of the 50 kDa NRG1 band by ANOVA.
However, levels were shown to be significantly lower in SCZ
compared to controls by T test. (p=0.0239) (Fig. 1D). This
supported our apriori hypothesis that reduced levels of the NRG1
intracellular fragment would be found in SCZ.
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between groups in the levels of the NTF 70 kDa in the
membrane fraction (Fig. 2A). In the soluble fraction, signifi-
cantly lower levels of the NRG1 50 kDa protein band were
observed in the affected cohorts compared to controls (Fig. 2)
ANOVA(F(2, 15)=6.596, p=0.010). Bonferroni post hoc test
showed controls significantly different from SCZ (p=0.018) and
BPD (p=0.022) (Fig. 2).
Figure 1. Levels of Neuregulin 1 (NRG1) in Brodmann’s area 9 (BA9). Representative western blots for each protein, with three samples for
each group, are shown. Densitometric analyses for all samples are shown above the western blot images. Values represent relative levels of protein
bands, normalized to sodium potassium ATPase for Full Length (FL), or beta actin for N-terminal fragment (NTF). 1A) NRG1 FL; 1B) NRG1 NTF; 1C)
Ratio of NTF/FL; 1D) NRG1 50 kDa. Controls (N), schizophrenia -SCZ (&), and bipolar disorder -BPD (m). 1C shows the NTF/FL to be significantly
higher, by Bonferroni post-hoc test, in the SCZ cohort compared to controls (p=0.011) and BPD (p=0.027). 1D shows NRG1 50 kDa levels are
significantly lower in SCZ compared to controls (T test, p=0.023). Asterisk indicates statistical significance. Graphs are plotted as mean 6 standard
error.
doi:10.1371/journal.pone.0036431.g001
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with NRG1 Cleavage Products
We measured levels of different known NRG1- cleavage
enzymes, namely ADAM17, ADAM19 and BACE1 that are
responsible for external cleavage, and Presenilin 1 (PS1) - the
catalytic subunit of gamma secretase, which is the enzyme that
cleaves NRG1 on the internal side. Levels of the external cleavage
enzymes were assessed in the soluble fractions, as these proteins
are known to be localized in both the membrane and cytosol
[26,27] and we had more protein available from the soluble
fraction. Pilot experiments showed that the expression patterns for
these enzymes were the same in both the membrane and soluble
fractions (data not shown). ANCOVA analyses showed that
ADAM17 was significantly different between groups after taking
pH as a covariate in BA9 (F (2, 15)=7.166, p=0.007) (Fig. 3A).
BACE1 and ADAM19 (Fig. 3B, 3C) were not significantly
different between groups in BA9. PS1 levels were measured in
the membrane fraction, as it has been found to be localized in the
plasma membrane [28]. In BA9, PS1 levels were found to be
significantly different in the control group compared to the
affected cohorts (Fig. 3D, E). Two distinct protein bands were
observed for PS1 (50 and 25 kDa). For the 50 kDa band, ANOVA
(F (2, 15)=12.551, p=0.001) with post-hoc Bonferroni test
showed significantly higher levels in both SCZ (p=0.003) and
BPD (p=0.001) (Fig. 3E). A similar observation was made with the
25 kDa band, where ANOVA (F (2, 15)=26.824, p,0.001) and
post hoc Bonferroni tests showed higher levels in SCZ and BPD
compared to controls (Fig. 3D). No significant differences were
observed in BACE1 or ADAM19 protein levels in BA9. No
significant differences between the groups were seen in the
hippocampal region in the levels of any of the cleavage enzymes
(not shown).
To ascertain if there was a relationship between the levels of
cleavage enzymes and NRG1 protein levels, correlation analyses
were carried out between the different NRG1 protein products
and cleavage enzymes respectively. Correlations were considered
significant when p,0.004, after correcting for multiple testing (12
correlations; 4 enzymes and 3 NRG1 protein products. In BA9,
levels of full length NRG1 protein were negatively correlated with
levels of ADAM17 (r=–0.547, p=0.019), with the SCZ cohort
showing a negative correlation (r=–0.926, p=0.008) that was not
seen in the other two groups (Fig. 4A). Levels of the 70 kDa NRG1
NTF band were positively correlated with levels of the PS1-
50 kDa in BA9, in the control cohort only (r=0.818, p=0.046)
(Fig. 4B), however this was not significant after correcting for
multiple testing. No correlations between NRG1 protein levels and
enzyme levels were observed in the hippocampus.
Correlations Between Symptom Clusters and Biological
Measures
To determine if the biological measures were associated with
specific symptomatology, we performed Pearson’s correlations
using the BISS and MADRS scales of symptom severity. We used
total severity scores for each scale and individual symptom factor
scores for the BISS. All samples, controls and patients, were
analyzed together based on symptom scores, since some of the
controls had basal levels of scores for these instruments. In BA9 we
found a positive correlation between ADAM19 levels and the
BISS psychosis factor (r=0.595 p=0.019) (Fig. 5A). PS1-50 kDa
levels showed a positive correlation with the mania factor
(r=0.535, p=0.040) (Fig. 5B). Depression scores measured by
MADRS also correlated positively with the PS1-50 kDa band
(r=0.567, p=0.027) (Fig. 5C). In the hippocampal region,
BACE1 showed a positive correlation with the BISS anxiety
factor (r=0.608, p=0.03) (Fig. 5D. Correlations are considered
Figure 2. Levels of Neuregulin 1 (NRG1) in the hippocampus. Values represent relative levels of NRG1, normalized to beta actin. 2A) NRG1
NTF; 2B) NRG1 50 kDa. Controls (N), schizophrenia -SCZ (&), and bipolar disorder -BPD (m). Bonferroni post hoc analyses show controls have
significantly higher levels of the soluble NRG1 50 kDa band compared to SCZ (p=0.018) and BPD (p=0.022). Asterisk indicates statistical significance.
Graphs are plotted as mean 6 standard error.
doi:10.1371/journal.pone.0036431.g002
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correlations; 4 enzymes and 3 NRG1 protein products (total 7) and
7 symptom measures). Importantly, when only patient samples
(excluding controls) were analyzed, the correlations were no longer
observed.
Discussion
In this exploratory study we aimed to determine whether
alterations in NRG1 protein cleavage and in expression of NRG1
cleavage enzymes are present in SCZ and BPD, and if so, is there
anatomical specificity. As stated by Boer et al, previous studies
have shown inconsistent results with regards to levels of different
NRG1 cleavage products [19]. Our approach was to use
membrane and soluble brain fractions to estimate levels of
membrane bound (full length, N-terminal fragment) and soluble
(intracellular domain) NRG1 products, and to investigate different
cleavage enzymes responsible for internal and external cleavage.
We also used a novel approach to identify correlations between
specific symptomatology and our biological findings, to identify
alternate phenotypes to the DSM (Diagnostic and Statistical
Manual, American Psychiatric Association) (DSM-IV-TR, 2000)
[29]. Using human post mortem brain tissue, we examined two
different brain regions, BA9 and the hippocampus, which have
been implicated in SCZ and BPD. BA9 of the prefrontal cortex
has been associated with deficits in cognitive dysfunction in SCZ
[30] and BPD [31]. The hippocampus regulates the process of
memory formation, which is known to be affected in both SCZ
and BPD patients [32]. Additionally, the role of NRG1 in the
hippocampus has been widely investigated [33–35].
Our results showed no significant differences in full length
NRG1 tethered to the membrane, but we did observe changes
when we compared the ratio of the external cleavage product to
the full length protein in BA9. We observed significantly higher
levels of the NTF/FL band ratios in the SCZ cohort, suggesting
that extracellular NRG1 processing is altered in SCZ. In support
of this, we observed that levels of ADAM17 were correlated
negatively with levels of full length protein in the SCZ cohort
compared to the control and BPD cohorts. Elevated levels of
ADAM17 could give rise to the higher levels of NTF (relative to
FL) in the SCZ cohort (also shown by significantly higher levels of
NTF in SCZ vs. controls by T test). However, we did not observe
a positive correlation between ADAM17 levels and NTF levels.
Figure 3. Levels of Neuregulin 1 (NRG1) cleavage enzymes Presenilin 1 (PS1) and ADAM17 in Brodmann’s Area 9 (BA9). Values
represent relative levels of protein bands, normalized to beta actin. 3A) ADAM17; 3B) BACE1; 3C) ADAM19; 3D) PS1 50 kDa; and 3E) PS1 25 kDa.
Controls (N), schizophrenia -SCZ (&) and bipolar disorder -BPD (m). 1A) shows levels of ADAM17 to be significantly different between cohorts by
ANCOVA [F (2, 15)=7.166, p=0.007]. 3D) and E) show PS-1 25 and 50 kDa levels are significantly lower in SCZ by Bonferroni post hoc analyses,
compared to controls (p=0.001) and BPD (p,0.001). Asterisk indicates statistical significance. Graphs are plotted as mean 6 standard error.
doi:10.1371/journal.pone.0036431.g003
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BACE1, ADAM19 and ADAM17, which cut on distinct sites of
the protein. However, the sequence in which these events take
place is not fully characterized. It is possible that cleavage of the
FL NRG1 by ADAM 17 occurs early on, while additional
enzymes or factors regulate formation of the final NTF fragment.
For example, cytokines such as IL-6 have been shown to regulate
cleavage of FL NRG1 [36]. This may explain why correlation of
ADAM17 was observed with reduced levels of FL, but not with
increased levels of NTF. Increased extracellular cleavage of NRG1
could potentially lead to aberrant activation of ErbB receptors and
signaling pathways such as the ERK, PKC and AKT pathways.
Increased activation of the ErbB4 receptor induced by NRG1 was
previously reported in a SCZ postmortem brain study [37]. Also,
increased activation of ERK2 has been reported in SCZ patients
[38]. The differences in NTF/FL and ADAM17 levels were not
observed in the hippocampus in SCZ patients, or in BPD in either
region. There is additional evidence in the literature of region
specific changes in NRG1 in schizophrenia. Gene expression of
NRG1 isoforms has been observed to be different in the prefrontal
cortex and hippocampus [39]. In a chemically induced- rat model
of schizophrenia, it was shown that NRG1-beta protein levels were
significantly higher in the CA1, CA3 and dentate gyrus in the
hippocampus, but only slight increases were seen in the prefrontal
cortex compared to the control group [40].
We observed significantly lower levels of the NRG1 50 kDa
band by ANOVA in the hippocampus in both affected cohorts,
and T tests showed significantly lower levels of this band in BA9 in
the SCZ cohort compared to controls. Although in a functionally
different brain region, this is consistent with previous results
obtained by Barakat et al, where lower levels of a NRG1 50 kDa
band were observed in the agranular frontal cortex region (BA6) in
SCZ patients [21]. We speculate that this 50 kDa band could be
the intracellular domain (ICD); however due to the lack of specific
antibodies against the ICD we cannot definitively ascertain the
identity of this band. Another study by Chong et al reported that
levels of a NRG1 53 kDa band (possibly the ICD) were increased
in the prefrontal cortex cytoplasmic fraction in SCZ patients [19].
This study did not specify the specific region within the PFC, so it
is possible that the observed differences in NRG1 levels compared
to our study may be due to different brain regions being used. The
results from these studies suggest that even within the frontal
cortex, there may be differences in NRG1 cleavage based on sub-
anatomical regions. Our laboratory previously reported the
finding of a NRG1 V.L transmembrane polymorphism that is
associated with SCZ [17]. This variant has now been found to
inhibit gamma secretase-induced release of the NRG1 ICD [9],
[41], and has also been shown to cause reduced cortical neuron
dendrite formation in vitro [41]. Inhibition of gamma secretase
cleavage of NRG1 has been shown to induce SCZ-like symptoms
in an animal model [9]. Our finding of decreased levels of the
NRG1 50 kDa band (possibly the ICD) in the SCZ cohort is
consistent with our apriori hypothesis that reduced levels of NRG1
intracellular cleavage would be observed in SCZ. However,
importantly, although we did not observe differences in levels of
the 50 kDa band in BA9 in the BPD cohort, we did observe
differences in this band in the hippocampus in BPD. The small
sample size we used, giving the study low power, could be the
reason for the non-significant results for the BPD cohort in BA9.
Alternatively, there could in fact be region-specific differences in
the role of NRG1 in SCZ and BPD. Additional studies using larger
cohorts are necessary to determine whether this is true. We also
hypothesized that changes in enzyme levels would correlate with
changes in NRG1 cleavage. However, we observed higher levels of
PS1 in the SCZ and BPD cohorts in BA9, as opposed to the lower
levels to be expected given the lower levels of the soluble 50 kDa
band (ICD). It is possible that the increase in PS1 levels is due to
increased extracellular cleavage, which generates the protein
product to be further cleaved by gamma secretase [25]. This may
also be an explanation of why levels of PS1 did not correlate with
the 50 kDa band levels, but were positively correlated with the
NTF band. An alternate explanation could be that lower levels of
Figure 4. Pearson’s correlation analyses between levels of Neuregulin 1 (NRG1) and NRG1 cleavage enzymes in Brodmann’s area 9
(BA9). A) ADAM17 and NRG1 full length; B) NRG1 NTF and PS1-50 kDa. Controls (N, —); SCZ (&,N—N); BPD (¤, –-). Inset shows R and p values for
the statistically significant cohort (represented by symbol) for each plot.
doi:10.1371/journal.pone.0036431.g004
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because of differences in levels of enzyme expression, but due to
alterations in activity of the gamma secretase enzyme (not tested),
or due to inherent NRG1 mutations, such as the V.L variant,
which may impede cleavage. This may also be the reason why we
did not observe changes in PS1 expression in the hippocampus
across the different cohorts, although differences in ICD levels
were observed. Further studies are necessary to determine the
specific cause of the observed alterations in levels of the NRG1
50 kDa band.
In summary, we have obtained preliminary results pointing
towards region-specific and disease-specific alterations in NRG1
cleavage in postmortem brain. We hypothesize that the region
specific differences we see may allude to the role of NRG1 in
different brain regions [38–39]. This may lead to differences in
pathology and symptomatology occurring in SCZ and BPD. Some
of our significant findings of altered NRG1 cleavage and enzyme
levels were observed in SCZ and not BPD, such as levels of
ADAM 17 and NTF being specifically higher in SCZ, compared
to BPD and controls. However, other findings, such as increased
levels of PS1, were seen for both SCZ and BPD in BA9.
Interestingly, when we analyzed the data using specific symptom-
atology criteria, we found positive correlations between levels of
PS1 and BISS mania scores, and PS1 and MADRS total scores in
Figure 5. Pearson’s correlation analyses between levels of NRG1 cleavage enzymes and symptomatology criteria. A, B, C) BA9; D)
hippocampus; A) ADAM19 and BISS5 (Psychosis); B) Presenilin-1 (PS1)-50 kDa and BISS2 (Mania); C) PS1-50 kDa and MADRS (Depression); D) BACE1
and BISS4 (Anxiety). Controls (N), SCZ (&) and BPD (m). R and p values were calculated based on symptomalogy score and protein expression,
regardless of DSM diagnosis.
doi:10.1371/journal.pone.0036431.g005
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associated with specific symptoms, which are present in both BPD
and SCZ, and argue in favor of the use of alternative phenotypes
when investigating the biological mechanisms of psychiatric
disorders. However, in all cases, our results may be confounded
due to the small sample sizes used, leading to low power, and
therefore the non-significant results may be false negatives. The
small sample size is also the reason for the large amount of
variability observed in some of the measures. Therefore, we
emphasize that the present results, while important, are pre-
liminary and must be interpreted with caution. These results must
be replicated using additional and larger cohorts.
In summary, NRG1 cleavage is a complex process that appears
to be regulated in an enzyme –dependent, region-dependent
manner, and investigating these pathways will help to gain a better
understanding of the role of NRG1 in psychiatric pathology.
While the small sample sizes we used is a great limitation, this
study is novel in that we examined levels of NRG1 cleavage
enzymes and levels of NRG1 protein in two psychiatric disorders
and two distinct brain regions. We encourage additional studies
with larger cohorts to validate these results. In addition, we hope
our exploratory studies with regards to correlation of enzyme
expression with specific symptoms encourages other researchers to
adopt a more holistic approach of utilizing symptomatology as
a useful adjuvant for studying the molecular mechanisms of
psychiatric disorders.
Materials and Methods
Postmortem Brain Samples
Postmortem brain tissue was obtained from the Southwest
Brain Bank, Department of Psychiatry UTHSCSA. Tissue
collection is under the auspices of the Anatomical Board of the
State of Texas, and all interactions involving living subjects are
regulated by the UTHSCSA Institutional Review Board. Next of
Kin interviews were conducted by a trained clinician using the
following instruments: Mini International Neuropsychiatric In-
terview (MINI) [21], Montgomery A ˚sberg Depression Rating
Scale (MADRS) [22] and the Bipolar Inventory of Signs and
Symptoms Scale (BISS) [23]. The BISS has 5 factors: depression,
mania, irritability, anxiety, and psychosis [42]. These instruments
assess symptoms experienced by the deceased in the last week of
life. Consensus diagnosis for all subjects was obtained by
reviewing medical records, toxicology reports and interview data
according to DSM-IV criteria by an independent panel of at
least three trained clinicians. Brain tissue was evaluated by
a neuropathologist and was found to be free of any confounding
neuropathology. Whole brains were dissected by cutting the
brain coronally into 1 cm thick sections, digitally photographed,
immediately frozen and stored in a –80uC freezer. From the
frozen blocks, dissections of prefrontal cortex Brodmann’s area 9
(BA9) from the right hemisphere were made from the superior
frontal gyrus, approximately 1.5 cm rostral to the genu of the
corpus callosum. For the hippocampal region, tissues were
sectioned using a cryostat and the rostral hippocampus region
was isolated. For the BA9 region a cohort of controls (no DSM-
IV diagnosis) (n=6), SCZ (n=6) and BPD (n=6) patients was
used. Of these brain samples, hippocampal tissue was only
available for n=4 controls, n=5 SCZ and n=5 BPD patients.
Therefore additional samples were added to each group such
that for the hippocampal region, a final cohort of controls (n=5),
SCZ (n=6) and BPD (n=6) patients was used. See Tables S1
and S2 for sample demographics.
Preparation of Membrane and Soluble Extracts
Protein samples were prepared using the Proteoextract Native
membrane protein extraction kit (EMD Biosciences, Gibbstown,
New Jersey) using 50 mg of frozen tissue and homogenization was
carried out using a Polytron PT-2100 bench top homogenizer
(Capitol scientific Inc. Austin, Texas) at 19000 rpm for 5 seconds.
Using a combination of different extraction buffers provided with
the kit, membrane and soluble fractions were collected, aliquoted,
and stored in –80uC. Protein concentrations were determined
using a microplate version of Bradford’s assay (Pierce, Thermo
scientific, Rockford, Illinois). All proteins were normalized for
equal amounts of total protein and prior to gel electrophoresis,
Laemmli buffer was added and samples were denatured at 95uC
for 5 minutes. The quality of the membrane and soluble fractions
was verified using antibodies against Sodium Potassium ATPase
(ab7671) from Abcam, San Francisco California (specific for
membrane) and ERK (sc-93) from Santa Cruz Biotechnology,
Santa Cruz California (specific for soluble fraction). No significant
cross contamination was observed between fractions (data not
shown).
Western Blot Analyses
Equal amounts of protein from the membrane (BA9 17 mg and
Hippocampus 26 mg) or soluble fractions (BA9 8 mg and
Hippocampus 17 mg) were loaded for each sample. Based on
standard curves, all the proteins assayed were within the linear
range of detection - Fig. S1. Proteins were separated on 4–20%
SDS polyacrylamide gels (Bio-Rad, Hercules,California) and
transferred overnight at 30 mV to Immobilon FL PVDF
membranes (Millipore, Billerica, Massachusetts). This was fol-
lowed by incubation with Odyssey blocking buffer (LI-COR
Biosciences, Lincoln, Nebraska) for 1 hour at room temperature
and then overnight incubation with primary antibodies : ab104800
(ADAM19), ab39162 (ADAM17), ab23796 (BACE1) and
ab71181(PRESENILIN1) from Abcam; NRG1 type III antibody
(AB5551) from Millipore, Billerica, Massachusetts; NRG1 C-
terminal antibody (sc-348) from Santa Cruz Biotechnology; A1978
(Beta Actin antibody) from Sigma Aldrich, St. Lewis, Missouri; ab
7671 (Sodium Potassium ATPase) from Abcam was used as
a loading control for our studies with full length NRG1. For all
other measurements, based on previous studies, beta actin was
used as loading control for both the membrane and soluble
fractions [43]. After overnight incubation, three washes were given
in phosphate buffered saline with 0.1%Tween 20 (PBS -tween) (10
minutes each) followed by incubation with fluorescently labeled
secondary antibodies (IR dye 800 Goat anti-Mouse IgG (H + L)
and IR dye 680 Goat anti-Rabbit IgG (H + L), from LI-COR
Biosciences. This was followed by a second set of washes in PBS-
tween and images were scanned on an Odyssey imager and
analyzed using the Odyssey software (LI-COR Biosciences) by
normalizing densities of the protein of interest to the loading
control. All proteins were assayed at least twice to ensure
consistency of results. Pictures of the entire blots with molecular
markers are shown in Fig. S2.
Statistical Analyses
Densitometry data from western blots for BA9 and hippocampal
regions were analyzed using SPSS 18 software (IBM Armonk,
New York). Data were log transformed and checked for normal
distribution using the Kolmogorov-Smirnov and Shapiro-Wilk
tests for homogeneity of variance and comparisons were made
with either ANCOVA or ANOVA followed by the Bonferroni
post hoc test and Pearson’s correlation analyses. Findings where
p,.05 are considered significant for ANCOVA and ANOVA. For
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correlations (4 enzymes and 3 NRG1 protein products) were
carried out, and therefore a p value of 0.05/12 or 0.0041 was
considered significant. For correlations with symptomatology,
a total of seven symptom measures were tested. Therefore
a p value of 0.05/49 or 0.001 was used as a cutoff.
Supporting Information
Figure S1 Standard curves for proteins assayed. Stan-
dard curves were generated for NRG1 FL, NRG1 NTF, PS1-
50 kDa, ADAM17, NRG1 50 kDa, BACE1 and ADAM19.
Range of protein loaded was 2–50 mg for membrane fraction,
and 2–40 mg for soluble fraction.
(TIF)
Figure S2 Gel blots of significant data with molecular
markers. Representative western blots for each protein assayed,
with three samples for each group are shown. Each blot is shown
with the corresponding beta actin loading pattern. NRG1 FL,
NRG1 NTF, PS1-50 and 25 kDa blots are from BA9 membrane
(mem) fraction. ADAM17 and NRG1 50 kDa blots are from BA9
soluble (sol) fraction. NRG1 50 kDa is from the hippocampus
soluble (sol) fraction.
(TIF)
Table S1 Sample Demographics for Brodmann’s area 9
(BA9). Table S1 represents demographic information for different
variables from BA9 region for the three different groups: Controls
(N=6), Schizophrenia (N=6) and Bipolar Disorder (N=6). This
includes Age, Sex, Race, PMI (post mortem interval) in hours (hrs),
Brain weight in grams (gms), pH, BISS (Bipolar Inventory of Signs
and Symptoms Scale) and, MADRS (Montgomery A ˚sberg
Depression Rating Scale). Total BISS score is cumulative of
BISS1-5 (1= depression, 2= mania, 3= irritability, 4= anxiety,
5= psychosis). * BISS and MADRS data was not available for one
sample in each group.
(DOCX)
Table S2 Sample Demographics for Hippocampus.
Table S represents demographic information for different
variables from hippocampal region for the three different groups:
Controls (N=5), Schizophrenia (N=6) and Bipolar Disorder
(N=6). This includes Age, Sex, Race, PMI (post mortem interval)
in hours (hrs), Brain weight in grams (gms), pH, BISS (Bipolar
Inventory of Signs and Symptoms Scale) and, MADRS (Mon-
tgomery A ˚sberg Depression Rating Scale). Total BISS score is
cumulative of BISS1-5 (1= depression, 2= mania, 3= irritability,
4= anxiety, 5= psychosis). * BISS data was not available for one
sample from the control group. ** shows the bipolar cohort to be
significantly different in age from the control cohort (p=0.004).
(DOCX)
Table S3 Sample medication data. Table S3 represents
medication data for different variables from all the subjects used
for our study. Variables shown include sample ID, Group
(Control, schizophrenia (SCZ) or bipolar disorder (BPD)); Tissue
availability (Brodmann’s area 9 (BA9) and/or hippocampus) and
the different classes of medications that the subjects were on,
including Antidepressant, Benzodiazapine, Neuroleptics and
Mood stabilizer denoted by Y-Yes or N-No.
(DOCX)
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